Chris Markoch

Chris Markoch

InvestorPlace Contributor

Chris Markoch is a freelance financial writer who brings over 25 years in sales and marketing to help find the story behind the stock. Chris starts by asking the question, “So what?” and then uses fundamental and (some) technical analysis to add depth to that insight.

Stepping back from the “what” allows Chris to bring perspective that helps investors make wise decisions based on their risk tolerance and investing timeline.

Markoch would describe his writing as being for investors more than traders. He looks at equities through a long-term lens and that is reflected in his writing.

In addition to his articles on InvestorPlace, you can also find Chris’ writing on MarketBeat.com where he has collaborated on the e-book “5 Investing Trends That Will Define the Market in 2022.” You can find Chris on LinkedIn and on Twitter.

Recent Articles

Don’t Buy Into the Fantasy of Chesapeake Stock

By Chris Markoch, InvestorPlace Contributor

Despite bankruptcy being a near certainty, CHK stock is drawing attention from buyers. Here's why it's a bad idea to indulge this fantasy.

PepsiCo May Offer Sturdy Shelter for the Upcoming Storm

By Chris Markoch, InvestorPlace Contributor

PEP stock was not spared as the Dow tumbled 1,800 points on June 11. But the stock should recover as investors look for defensive stocks.

Wait for More Data Before Buying Paycom Software

By Chris Markoch, InvestorPlace Contributor

Although the May jobs report initially has positive implications for PAYC stock, the fine print in the employment numbers makes this a tricky bet.

It’s Game on for Advanced Micro Devices Stock in a Post-Lockdown World

By Chris Markoch, InvestorPlace Contributor

AMD stock has been surging during the Covid-19 pandemic. However, partnerships in the video game sector will give AMD a catalyst into 2021.

7 Great Biotech Stocks to Buy and Hold Now

By Chris Markoch, InvestorPlace Contributor

As investors begin to turn their attention away from Covid-19 and the novel coronavirus, these biotech stocks present excellent opportunities.

This Is No Time to Be Speculating on Ocugen

By Chris Markoch, InvestorPlace Contributor

Ocugen's ambitions are not gaining traction in an environment where most biotech investors are focusing on Covid-19. Thus, the case for OCGN stock is unusually risky.

DocuSign Stock May Be Overdone, but It’s Still a Great Long-Term Buy

By Chris Markoch, InvestorPlace Contributor

DocuSign stock soared as companies made arrangements to remotely share secure documents. But the stock looks like it's ready to take a break.

There Are 40 Billion Reasons to Stay Away from Occidental Petroleum

By Chris Markoch, InvestorPlace Contributor

Although rising oil prices have supported the recent rally in OXY stock, the long-term picture is less encouraging.

Nokia’s Bullish Run Is About to Come to an End

By Chris Markoch, InvestorPlace Contributor

Nokia stock climbed nearly 75% since March, but with a suspended dividend and a downward profit revision, NOK's run may be over.

Luckin Coffee Is Not Investable at This Time

By Chris Markoch, InvestorPlace Contributor

Investors may be able to overlook accounting fraud, but there’s a more fundamental problem for LK stock.

Load More